Continue the same study drug if it’s helping you
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial is for people who already finished a Zenith Epigenetics study with the drug ZEN003694 and are still getting benefit. It checks whether continuing the same treatment on schedule is safe and useful for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You finished the original ZEN003694 study in the parent trial
- Your study doctor felt the treatment was helping you at the start of this new trial
- Your daily activity level is good (ECOG score 0 or 1, meaning you’re fully active or limited but not confined)
- You tolerated the drug well enough to keep taking it (as your study doctor decides)
- You can start dosing in this continuation trial within 14 days of finishing the parent study (unless the sponsor approves a later start in writing)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (TYK-00540) combined with enzalutamide for men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It may be an option if you have tried only one other newer hormone treatment and it failed.
This study lets people who were in an earlier Exelixis cancer treatment trial continue receiving the same treatment if it's still helping them. It's designed to see how safe and effective the treatment is over a longer period.
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
This trial lets people who were already in a related “parent” study either keep taking treatment or restart it after it had stopped working for a while. It’s meant for people who previously had a meaningful response and may still benefit from continued treatment.
This trial tests a new combination of drugs (ZEN-3694 and enzalutamide) for men with advanced prostate cancer that has stopped responding to standard hormonal treatments. It aims to see if this combination can help slow or stop the cancer from growing.
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Hear when a new mCRPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.